{"classes":[{"categories":[{"measurements":[{"comment":"\\<75% of participants experienced the event within the treatment arm. Hence, third-quartile could not be derived.","groupId":"OG000","lowerLimit":"7.9","upperLimit":"NA","value":"17.1"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"22.2","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"OS is defined as the time from date of first dose of study treatment to the date of death by any cause.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. Only those participants with data available at specified time point were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 54 months","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}